Market Advisors Research predicts potential rise in VitaminSpice's share value

NewsGuard 100/100 Score

VitaminSpice  (OTC Bulletin Board: VTMS) (German WKN: A0YCND) (www.VitaminSpice.net) is pleased to announce that Market Advisors Research has begun coverage of VitaminSpice with a very favorable report and predicts a potential rise in the valuation of the shares to $1.25 based on the continuing developments of the Company's fundamentals.

The editors of Market Advisors have tremendous credentials including, but not limited to, being rated numerous times by The Wall Street Journal, Hulbert Financial Digest and the Timer Digest, among others, as one of the best market timers, top bond timers and having one of the nation's best model portfolios.

Mr. Bukstel, President and CEO of VitaminSpice, Inc. stated, "We at VitaminSpice are pleased that a research firm such as Market Advisors has taken a strong and positive opinion of our organization.  To know that respected individuals in the investment community continue to monitor our development and are willing to confirm their beliefs on the future of our organization is truly exciting."

In its report, Market Advisors made reference to several key factors including the addition to VitaminSpice's team of a true icon in the retail industry,  Bill Fields, former CEO of Walmart Stores; VitaminSpice being rated as one of the top tasting spices in America by Masters of Taste; and the recent agreement with Amdistco for co-branding Iron Chef, as reasons for its favorable outlook on VitaminSpice.

Source:

VitaminSpice

Posted in:

Tags: ,

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research confirms no association between SARS-CoV-2 and childhood asthma diagnoses